Objective: To investigate the effect of simultaneous administration of [6S]-5-methyltetrahydrofolic acid ([6S]-5-CH 3 H 4 PteGlu) with L-ascorbic acid (L-AA) on serum folate concentrations in healthy male subjects. Subjects and methods: A total of nine healthy male volunteers were recruited. Serum folate concentrations were measured before and up to 8 h after administration of each treatment (1) 
Introduction
Folates are essential cofactors required for one-carbon transfer reactions in key biosynthetic and epigenetic processes (Stover, 2004) . Folate deficiency is prevalent in underdeveloped countries, and even in the Western world, subtle deficiency is a public health problem most notable in its association with the prevention of neural tube defects (NTDs) (Czeizel and Dudas, 1992; Eichholzer et al., 2006) . Folates also attract considerable interest as protective vitamins against pregnancy complications, certain types of cancer (Kim, 1999) , cardiovascular disease (Moat et al., 2004) and some neuropsychiatric conditions (Selhub et al., 2000; Seshadri et al., 2002) . Mandatory fortification of staple foods with folic acid (PteGlu) was introduced, for example, in the US, Canada and Chile and resulted in a significantly decreased prevalence of NTDs plus a reduction of plasma total homocysteine (tHcy) levels in the US population (Honein et al., 2001) . Despite these results, fortification has not yet been implemented in many other countries because of concerns that excessive PteGlu intake may mask vitamin B 12 deficiency and enhance undiagnosed existing neoplasms (Wright et al., 2001; Kim, 2004; Cornel et al., 2005) . It is well established that folate absorption at physiological intraluminal concentrations is governed by a saturable carriermediated, pH-and energy-dependent transport mechanism in the proximal small intestine, whereas a non-saturable diffusion-mediated transport system plays a major role in folate absorption at concentrations above 20 mmol/l (Selhub et al., 1984; Gregory, 1995; Said, 2004) . Unlike other epithelial transport mechanisms, the mucosal system appears to be unique in its lack of hierarchy of transport, having a similar affinity for both oxidized (that is, PteGlu) and reduced natural folate forms (Said et al., 1987) . Exposure to doses of PteGlu above 589 nmol results in occurrence of unmetabolized PteGlu in systemic circulation (Kelly et al., 1997) that can be converted to tetrahydrofolic acid (H 4 PteGlu). This would mask the hematological abnormalities related to vitamin B 12 deficiency, delaying its diagnosis and allow the associated neurological dysfunction to progress to an irreversible combined degeneration of the spinal cord. Hereto, improving the bioavailability and intake of natural monoglutamyl folates could be an alternative to improve folate status, given that it is unlikely that natural vitamers would mask vitamin B 12 deficiency (Wright et al., 2001; Jagerstad et al., 2005) (Venn et al., 2002; Lamers et al., 2006) and on lowering tHcy (Venn et al., 2003; Lamers et al., 2004) .
[6S]-5-CH 3 H 4 PteGlu, however, exhibits a significant instability toward oxygen and low pH, resulting in oxidation to 5-methyldihydrofolate (5-CH 3 H 2 PteGlu) (Donaldson and Keresztesy, 1962) , that is absorbed in the gut but does not appear to enter the folate metabolic pool (Thien et al., 1977) . In addition, 5-CH 3 H 2 PteGlu is rapidly degraded in the acid-peptic gastric environment, resulting in significant losses of folate during digestion (Lucock et al., 1995; Seyoum and Selhub, 1998) . Since antioxidants such as L-ascorbic acid (L-AA) convert 5-CH 3 H 2 PteGlu into 5-CH 3 H 4 PteGlu (Donaldson and Keresztesy, 1962; Lucock et al., 1995) and protect [6S]-5-CH 3 H 4 PteGlu against oxidative degradation (Oey et al., 2006) , it has been stated that normal endogenous gastric L-AA concentrations, as secreted in the gastric lumen, might be a critical factor in optimizing the bioavailability of natural folate (Thien et al., 1977; Lucock et al., 1995) . However, in vivo evidence regarding the influence of L-AA on natural folate bioavailability is limited to long-term studies in which L-AA supplementation has indirectly been related to an enhancement of blood folate indices in elderly (Bates et al., 1980; Kyllastinen et al., 1990) . In addition, recent findings have shown that L-AA can also enhance the efficiency of PteGlu supplementation to raise folate status in smoking middle-aged blood donors (Cafolla et al., 2002) . Since the latter findings suggest the occurrence of an enhancing interaction between L-AA and folate intake, the purpose of the current investigation was to study whether simultaneous oral intake of 
Subjects and methods

Subjects
Healthy male subjects (18-40 years) were recruited through advertisements and interviewed using a health history questionnaire. Screening venous blood samples were collected after an overnight fast (10 h). Eligibility criteria for the subjects were as follows: absence of health complaints or chronic diseases, not following a restricted diet, low or moderate alcohol intake (o21 consumptions/week), no use of mineral/vitamin supplements (inclusively PteGlu), BMI between 18 and 30 kg/m 2 , no use of anticonvulsant, antiinflammatory and antacid drugs, adequate vitamin B 12 (plasma cobalamin X110 pmol/l) and folate status (serum folate X6.8 nmol/l, erythrocyte folate X0.3 mmol/l) and tHcy p15 mmol/l. A total of 20 volunteers were recruited. The study sample size was calculated before the study to detect a relevant difference of 25% in total serum folate response with power 80% (a ¼ 0.05) based on results for [6S]-5-CH 3 H 4 PteGlu bioavailability in healthy men . The Medical Ethical Committee of the Katholieke Universiteit Leuven granted approval for the research and written informed consent was obtained from each subject before the beginning of the study. (Oey et al., 2006) . The 973.8 mg dose of L-AA was chosen because it was suggested to interfere with folate metabolism (Mix, 1999) .
Study design
Acute folate absorption was assessed by measuring serum folate concentrations during an 8 h period following treatment administration. Hereto, [6S]-5-CH 3 H 4 PteGlu Ca-salt (Metafolin) was supplied by Merck Eprova (Schaffhausen, Switzerland) and reconditioned at the university hospital's pharmacy into ready-made randomly coded 'treatment powders', consisting of lactose plus the according L-AA and/or [6S]-5-CH 3 H 4 PteGlu dose. On test days, treatment powders were freshly dissolved in 25% glucose solutions (B Braun, Diegem, Belgium) and ingested under supervision after an overnight fast (10 h) before breakfast. Aliquots of the solutions were frozen in liquid nitrogen and stored at À801C until determination of [6S]-5-CH 3 H 4 PteGlu and L-AA content using Reversed phase-high-performance liquid chromatography (RP-HPLC) (Liau et al., 1993; Oey et al., 2006) . Inter-assay variations for [6S]-5-CH 3 H 4 PteGlu and L-AA analysis were 5.0 and 1.4% (n ¼ 10), respectively.
To minimize within-subject variation of baseline serum folate concentrations among treatments and to saturate the subjects body folate pools, each treatment was preceded by a 5-day saturation regimen (2 mg/day [6S]-5-CH 3 H 4 PteGlu), followed by two [6S]-5-CH 3 H 4 PteGlu-free days. To exclude 'carry-over' effects, a 6-day washout period was implemented after each treatment. Compliance was assessed by recording the subject's consumption of folate supplements in a diary. Saturation supplement capsules (1 mg [6S]-5-CH 3 H 4 PteGlu/ capsule) were manufactured in one batch at the university hospital's pharmacy as hard gelatin capsules containing 99 mg lactose and 1 mg [6S]-5-CH 3 H 4 PteGlu from the same batch previously used for the production of treatment powders. Supplements were packed per 10 in coded boxes. Both treatment powders and supplements were stored at À401C during the study, whereas subjects stored the supplements refrigerated during saturation periods. Stability tests using RP-HPLC (Oey et al., 2006) showed 99% recovery of [6S]-5-CH 3 H 4 PteGlu for capsules stored at À401C during the study period.
Diet
To control dietary folate intake during treatment days, subjects consumed a standardized low-folate diet (Table 1) , providing 80% of the energy requirements for men with sedentary lifestyle (Seeuws et al., 1995) . Participants were allowed to drink water ad libitum. The diet was purchased as one batch at the beginning of the study and stored under refrigerated (41C) or freezing (À401C) conditions. On test days, lunch meals were cooked in a microwave oven (2000 W, 15 min) and subsequently heated in an oven (2001C, 20 min) . Folate content of the diet was determined using a tri-enzyme extraction Lactobacillus casei folate assay (Tamura, 1998) .
Blood sampling and analysis
To prevent multiple venipuncture, a venous catheter attached to a flexible extension line with clamp and multiple blood sampling system (Bionector-S, Vygon, Ecouen, France) was placed in a dorsal hand vein. Venous blood samples were collected before (baseline) and after administration of the treatments at predetermined time intervals, that is, after 0.5, 1, 1.5 and 2 h (before mid-morning snack), after 2.5, 3 and 4 h (before lunch), after 6 h (before afternoon snack) and after 8 h. Samples were clotted for 45 min to obtain serum after centrifugation (41C, 2200 g, 10 min). Serum was immediately frozen in liquid nitrogen and stored at À801C until analysis. tHcy concentrations were determined at screening using enzyme-linked immunosorbent assay (Axis-Shield, Dundee, UK) (Sundrehagen, 1990) . Quality control was provided by repeated analysis of control samples covering a broad range of concentrations. Serum folate, erythrocyte folate and plasma vitamin B 12 concentrations were measured using automated electro-chemiluminescence immunoassays (Elecsys 2010; Roche Diagnostics, Mannheim, Germany). Calibration control of the serum folate assay was conducted by measurement of commercial folate calibration controls (Folate II CalSet II; Roche Diagnostics). Quality control for the serum folate assay was performed using pooled folate control samples (PreciControl Universal; Roche Diagnostics), showing total and intra-coefficients of variance (CVs) of 3.2 and 2.3% (n ¼ 24), respectively. Additional quality control was performed by repeated measurements of a pooled subjects' serum sample during the runs needed to analyze the subject sample series (intra-assay CV ¼ 1.5%, n ¼ 6, total CV ¼ 3.5%, n ¼ 26). All samples collected from each subject were analyzed for serum folate in one assay to eliminate inter-assay measurement variation.
Statistical analysis
Serum folate response values for each treatment were calculated on an individual basis by subtracting the pre-dose (baseline) serum folate concentration from the concentration at each time point. To estimate the dose rise in serum (Seeuws et al., 1995) . b Determined with a microbial folate assay after tri-enzyme extraction (Tamura, 1998 , respectively. L-AA was undetectable in treatment 1 (n ¼ 4) and 2 (n ¼ 4). Duplicate folate analysis of the diet yielded results below the detection limit of the assay (7 mg/100 g), indicating a maximal dietary folate intake of 47 mg during treatments. The total L-AA content of the diet was estimated as 4.5 mg based on food composition tables (Seeuws et al., 1995) .
Serum folate response to treatments
Among the initially recruited subjects (n ¼ 20), nine healthy men were eligible to participate in the study. Subject characteristics of this group are presented in Table 2 . Out of nine subjects, one participant was a heavy smoker (20 cigarettes/day), the other subjects were non-smokers. Serum and erythrocyte folate concentrations, vitamin B 12 status and tHcy concentrations determined at screening were within normal reference ranges. Compliance to the saturation regimen (8971%) did not significantly differ among treatments. Serum folate concentrations at baseline and up to 8 h during treatments are presented in Table 3 . Baseline serum folate concentrations were not significantly different among treatments (P ¼ 0.59) and increased within 30 min after [6S]-5-CH 3 H 4 PteGlu consumption (treatments 2, 3 and 4), showing no delay in acute folate absorption. No significant differences in serum folate concentrations were observed during placebo (P ¼ 0.54). Post hoc comparisons of serum folate concentrations at each time point vs baseline showed a longer raise in serum folate concentration after administration of treatments 3 and 4 than after treatment 2 (6 vs 4 h, Po0.05). In all treatments, serum folate concentrations returned to baseline by 8 h (Table 3) . Serum folate response vs time for all treatments is shown in Figure 1 . R max values were mostly established between 30 and 90 min postprandially and were significantly different between treatments 4 and 2 (11.1270.90 vs 7.957 0.49 nmol/l, Po0.05). No significant difference in R max was found between aforementioned treatments and treatment 3 (10.4070.92 nmol/l, P40.05). As expected, the AUCs for folate treatments were significantly greater than the placebo AUC (À3.575.4 h nmol/l) (Po0.001) (Figure 2 ). The estimated total folate response of [6S]-5-CH 3 H 4 PteGlu in serum was significantly higher after consumption of treatment 3 or 4 as compared to treatment 2 (respectively 46.574.0 and 53.074.0 vs 34.373.8 h nmol/l, Po0.05), whereas no significant difference was found between treatments 3 and 4 (P ¼ 0.47). Ingestion of [6S]-5-CH 3 H 4 PteGlu with 973.8 and 289.4 mg L-AA resulted in a significant increase of the AUC with 18.7 h nmol/l (95% confidence interval (CI), 9.8-27.6 h nmol/l) and 12.3 h nmol/l (95% CI, 3.3-21.2 h nmol/l), Pentieva et al., 2004) , using measurement of serum or plasma folate responses after an oral folate dose to express the AUC relative to an equivalent PteGlu dose. This methodology has been accepted as a valuable indicator for short-term folate bioavailability when the post-dosing measurement period allows adequate characterization of the AUC (X80%) (Cahill et al., 1998) . Despite this general acceptance, recent reports have questioned the validity of PteGlu as reference in AUC protocols Melse-Boonstra et al., 2004; Wright et al., 2005) since a substantial portion of the plasma response after consumption of 13 C 5 -PteGlu or 13 C 5 -5-formyltetrahydrofolate does not originate from the test dose, and secondly since plasma response kinetics among PteGlu and natural folates largely differ (Wright et al., 2003 (Wright et al., , 2005 . Alternatively, we considered [6S]-5-CH 3 H 4 PteGlu since its appearance in circulation is unlikely to depend on interconversion reactions (de Meer et al., 2005) . It should be noted that using 'unlabeled' [6S]-5-CH 3 H 4 PteGlu did not allow a distinction between the response originating from the dose and the endogenous response caused by displacement of folate from body pools (Wright et al., 2003) and that interpretation of the current results is hence somewhat challenging. Comparison of the influence of L-AA on these responses was, however, outside the scope or the current preliminary investigation.
With regards to methodology, treatments were randomly administered in standardized experimental conditions with a scheduled low-folate diet to ensure identical physiological and dietary conditions on each test day, preventing variability caused by disrupted enterohepatic circulation provoked by fasting (Pietrzik et al., 1990) . Saturation of the subject's body folate pools prevented specific upregulation of folate uptake among the test days (Venn et al., 2002) , assured a measurable folate response (Pfeiffer et al., 1997) and minimized differences in baseline serum folate concentrations among test days. Neither the amount of folate in the standard diet, nor the saturation regimen with supraphysiologic doses of [6S]-5-CH 3 H 4 PteGlu affected the folate response in view of the fact that serum folate concentrations did not differ from baseline during the placebo treatment. In accordance with other studies (Prinz-Langenohl et al., 2003; Pentieva et al., 2004) , oral [6S]-5-CH 3 H 4 PteGlu administration resulted in peak serum folate concentrations within 2 h postprandially, which returned to baseline after 4-8 h. Owing to very large inter-method and inter-laboratory differences among serum folate determination methods (Gunter et al., 1996) , further comparison of results would require calibration standardization and assessment of interlaboratory variation (that is, it has been shown that the Elecsys assay reads 'low' among the automated methods that are in current usage (Owen and Roberts, 2003) ).
The observed influence of L-AA on serum folate responses is indirectly supported by previous research showing that concurrent L-AA and PteGlu supplementation improves the effectiveness of PteGlu in enhancing folate status (Cafolla (Bates et al., 1980; Kyllastinen et al., 1990) . Up to date, however, it was not known if simultaneous consumption of L-AA with natural folate would influence the folate response and hence a physiological explanation for the current finding remains suggestive. Since [6S]-5-CH 3 H 4 PteGlu bioavailability is incomplete (Witthöft et al., 2003) and since gastric L-AA concentrations are crucial for 5-CH 3 H 4 PteGlu stability/bioavailability (Lucock et al., 1995) , it could be suggested that increased gastric antioxidant capacity due to L-AA administration resulted in a higher amount of folate available for absorption after gastric passage. However, as L-AA has been shown to enhance the efficiency of PteGlu supplementation (Cafolla et al., 2002) , one could surmise that L-AA could influence folate metabolism differently since PteGlu is not prone to oxidation at gastrointestinal conditions. Within this context, it is well established that serum folate responses depend on several metabolic processes, that is, 'liver first-pass' effect, enterohepatic circulation, biliary and urinary excretion and on displacement of endogenous body folate (Gregory, 1995) . Currently, it is not known whether L-AA can influence some of these processes. This hence calls for further investigations using isotopic labeled [6S]-5-CH 3 H 4 PteGlu and PteGlu plus L-AA control treatments. Measurement of total and isotopic folate enrichment in serum would allow accurate determination of the origin of the response, whereas L-AA treatments without folate administration may provide insight into the potential effect of L-AA on, for example, enterohepatic folate recirculation. Thirdly, increased luminal L-AA concentrations could have modulated the intestinal folate transport system, which has recently been identified as a protoncoupled high-affinity folate transporter with low pH optimum (Qiu et al., 2006) , resulting in an upregulation of the rate/extent of folate uptake. Validation of this assumption requires further investigations regarding the influence of luminal L-AA concentrations on folate absorption mechanism. It should, however, be noted that in the present investigation, no further data are available to test these hypotheses and that other explanations remain possible.
In conclusion, this study indicates that concurrent administration of L-AA (X289.4 mg) significantly improved the serum folate response to a physiological [6S]-5-CH 3 H 4 PteGlu dose in our sample of healthy young men. As the administered dose of [6S]-5-CH 3 H 4 PteGlu was relatively large, the current results may have relevance to clinical therapies, for example, supplementation. Extrapolation of the results, however, should be performed with care and calls for long-term studies since short-term protocols cannot predict the slow turnover rates of major body folate pools (Gregory, 2002) . In addition, the currently used experimental conditions cannot predict short-term kinetic behavior of folate at more nutritionally relevant intakes, as in the case where [6S]-5-CH 3 H 4 PteGlu may be used to fortify foods. Moreover, despite the positive effect on the appearance of folate in serum, it should be considered that doses of L-AA above 500 mg may adversely interfere with the availability of vitamin B 12 from food and thus compromise the beneficial role of folate in tHcy metabolism (Mix, 1999) . As a consequence, future research to unravel the effect of vitamin C on the bioavailability and/or bioefficiency of folate should account for this putative negative effect.
